BioSpace News Archive

Acer Therapeutics Inc. (Nasdaq: ACER) today announced that topline results from its Phase 2a proof of concept clinical trial to evaluate ACER-801 (osanetant).

The Porex Life Sciences Institute announced today during the 2023 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting that it is expanding the availability of its Saletto® Oral Fluid Collection Device to the genetic and genomic testing market.

BRAINBox Solutions today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance to issue to the company a broad patent covering a specific set of biomarkers that correlate to specific neuroimaging findings by standard or advanced MRI methods.

Alvotech (NASDAQ: ALVO) today announced the presentation of two posters related to its clinical studies in support of biosimilarity and clinical comparability of Alvotech’s ATV04 (ustekinumab) and the reference product Stelara® at the 2023 American Academy of Dermatology (AAD) Annual Meeting, March 17-21 in New Orleans.

Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines called prescription digital therapeutics, announced that it is engaged in a process to explore strategic alternatives to maximize shareholder value.

Healthcare Integrated Technologies, Inc. (“HiTC”), a leading innovator of healthcare technology solutions, is proud to announce the approval of U.S. Patent 11,587,423, issued on February 21, 2023.

Bioretec Ltd has published its 2022 Annual Report, Report by the Board of Directors, and Financial Statements.

DermaSensor Inc., a health technology company equipping primary care physicians (PCPs) with a non-invasive device for use in evaluation of suspicious skin lesions, presented a pooled analysis today from two clinical studies evaluating the performance of the company’s device in detecting skin cancer.

HilleVax, Inc. reported financial results for the year ended December 31, 2022, highlighted recent program progress, and outlined key upcoming milestones for HIL-214, the company’s investigational virus-like particle based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis.

Pharma-Bio Serv, Inc. announced that revenues for the quarter ended January 31, 2023 were approximately $4.2 million, a net decrease of approximately $0.8 million when compared to the same period last year.